Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective: Executive summary

D P. Faxon
J W. Eikelboom
P B. Berger, Zucker School of Medicine at Hofstra/Northwell
D R. Holmes
D L. Bhatt
D J. Moliterno
R C. Becker
D J. Angiolillo

Abstract

The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognized that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations, given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis, and major bleeding. This executive summary describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton pump inhibitors, and the use and duration of triple therapy after stent placement, based on the risk assessment. © 2011 American Heart Association, Inc.